Physician profile
Saima Butt
NPI 1205032364
$4,840.50
in general payments reported to CMS, 2019-2025
31 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $927 · 2023: $1,052 · 2024: $1,679 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,913.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $897.04 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $827.03 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $774.13 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $265.77 | 2023-2025 | |
| Pfizer INC. | $255.63 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $217.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $201.28 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $198.34 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $162.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $144.49 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.06 | 2023-2025 | Caplyta |
| Astellas Pharma US INC | $100.37 | 2024-2025 | Veozah |
| Abbott Laboratories | $96.69 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $73.84 | 2022 | |
| Amgen INC. | $70.33 | 2024 | Prolia, Evenity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.95 | 2023 | |
| Dynavax Technologies Corporation | $43.11 | 2022-2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.89 | 2024 | Jardiance |
| Hologic Sales and Service, LLC | $34.87 | 2022-2023 | Thinprep 2000 Processor, Aptima |
| Currax Pharmaceuticals LLC | $32.61 | 2025 | Contrave |
| Cranial Technologies, INC | $31.58 | 2024 | Doc Band |
| Lundbeck LLC | $30.82 | 2024 | Rexulti |
| Boston Scientific Corporation | $29.17 | 2025 | Wavewriter Alpha Prime 16 |
| Nestle Healthcare Nutrition INC. | $24.84 | 2023 | |
| Amarin Pharma, INC. | $23.62 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.31 | 2024 | Evkeeza |
| Sanofi Pasteur INC. | $20.29 | 2022 | |
| Eisai INC. | $19.02 | 2023 | |
| Seqirus USA INC | $17.49 | 2024 | Fluad, Flucelvax |
| Shield Therapeutics INC | $15.28 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.